MetaCap

Vyome Holdings Inc. (HIND)

NASDAQ: HINDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.20-0.25 (-17.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HIND stock chart

Technical analysis

Key statistics

All statistics
52-week range
1.20 – 5.88
Day range
1.20 – 1.43
Volume / Avg
35.01K / 13.92K
Beta
—

52-week range

$1.20$5.88

HIND stock today

Vyome (HIND) closed at $1.20 on Nov 20, down 17.24% (-$0.25), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 35.01K shares, a sign of unusually heavy trading. Shares are 79.6% below their 52-week high of $5.88, set on Dec 8, 2025 and 0.0% above the 52-week low of $1.20, near the bottom of the past year's range.

HIND is down 65.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 75.9%. Vyome trades at 0.3x its trailing twelve-month earnings per share of $4.77.

Summary generated from market data by MetaCap's automated system. Methodology

About Vyome

Company profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Venkateswarlu Nelabhotla M.B.A.
Headquarters
Cambridge, MA
Employees
9
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Vyome generated $319,714 in revenue, up 24.4% from fiscal 2024. Vyome reported a net loss of $10.3 million, compared with a loss of $1.4 million a year earlier. Gross margin was 68.4% (down from 75.9%) and operating margin -3269.4%.

Vyome annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$319.71K$256.94K$8.68M$11.24M$13.60M
Growth+24.43%-97.04%-22.79%-17.35%+20.36%
Net income$-10.26M$-1.45M$-11.39M$-46.21M$-63.15M
EPS (diluted)$-4.86$-6,001.39$-110.87$-108.90$-288.97

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$8.83+635.83%

  • Strong buy 1
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.50High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.13 vs —

HIND news

All HIND news

Vyome peers

Health Care sector
HIND peer companies
CompanyPrice% ChgMarket capCompare
LEXXLexaria Bioscience Corp.4.03-10.24%$8.49Mvs HIND
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares1.29-9.15%$8.29Mvs HIND
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs HIND
MBRXMoleculin Biotech Inc.7.74-2.40%$8.22Mvs HIND
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs HIND
PTNPalatin Technologies Inc.4.58-7.10%$8.16Mvs HIND
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs HIND
DAREDare Bioscience Inc.0.4074-9.87%$8.01Mvs HIND

Indexes, lists and sector

Vyome stock FAQ

What is Vyome's stock price today?

HIND last traded at $1.20 as of Nov 20, 4:00 PM EST, down 17.24% on the day. Prices are delayed at least 15 minutes.

Does Vyome pay a dividend?

No. Vyome does not currently pay a regular cash dividend.

What is HIND's P/E ratio?

HIND trades at a trailing P/E ratio of 0.25.

Who is Vyome's CEO?

Mr. Venkateswarlu Nelabhotla M.B.A. is the chief executive officer of Vyome Holdings Inc., which has about 9 employees.

Has HIND ever split its stock?

Yes. The most recent HIND stock split was a 1-for-4 split on Aug 15, 2025, one of 5 splits on record.

What is the HIND 52-week high?

The 52-week high for HIND is $5.88 and the 52-week low is $1.20. The stock is currently 79.6% below its high.

Compare HIND